Brief: Jiangsu Recbio Technology Says Positive Results Achieved For Primary Vaccination Phase II Study In Philippines
08/11/2022 05:57
Nov 8 (Reuters) - Jiangsu Recbio Technology Co Ltd
2179.HK :
* POSITIVE RESULTS ACHIEVED FOR PRIMARY VACCINATION PHASE II
STUDY
IN PHILIPPINES
* POSITIVE RESULTS ACHIEVED IN HETEROLOGOUS BOOSTER
VACCINATION
PHASE II STUDY IN UAE FOR RECOMBINANT COVID-19 VACCINE RECOV
* STUDIES SHOWED RECOV DEMONSTRATED GOOD SAFETY PROFILE,
EXCELLENT
IMMUNE RESPONSE
Source text for Eikon: urn:newsml:reuters.com:*:nHKS1RJh8J
Further company coverage: 2179.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jiangsu Recbio Technology
See all newsBrief: Jiangsu Recbio Technology To Re-Plan Timetable For HPV Vaccine Marketing Application
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares